BUCHAN CONSULTING PTY LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting 2022-04-07 09:34
Alterity Therapeutics to Present at the 34th Annual Roth Conference 2022-03-07 20:59
Prota Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients 2022-02-09 20:00
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease 2022-01-28 20:08
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report 2022-01-27 20:45
Trajan Group acquires Neoteryx LLC 2022-01-11 00:00
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's 2022-01-06 20:30
Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference 2022-01-05 20:45
Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial 2021-12-14 20:25
Trajan to acquire LEAP PAL Parts 2021-12-09 21:00
Trajan Group acquires Axel Semrau GmbH 2021-11-22 23:30
Alterity Therapeutics to Participate in Two Upcoming Investor Conferences 2021-11-22 20:50
Investment Confidence in Icon Group to Drive Next Phase of Global Growth With EQT Infrastructure Investment 2021-11-19 09:19
Planet Innovation acquires BIT Group's North American operations, doubling its medtech manufacturing capacity 2021-11-12 07:44
Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021 2021-11-09 20:30
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases 2021-11-05 14:57
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases 2021-11-04 19:30
Appendix 4C - Q1 FY22 Quarterly Cash Flow Report 2021-10-29 14:50
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program 2021-10-20 05:08
Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 2021-09-20 22:51
1 2 3 4